Anti-PGC1 alpha antibody [PPARAH6] (ab51365)

Overview

  • Product nameAnti-PGC1 alpha antibody [PPARAH6]
    See all PGC1 alpha primary antibodies
  • Description
    Mouse monoclonal [PPARAH6] to PGC1 alpha
  • Tested applicationsSuitable for: Dot blot, WBmore details
  • Species reactivity
    Reacts with: Mouse
    Predicted to work with: Human
  • Immunogen

    Recombinant fragment corresponding to Human PGC1 alpha (C terminal).
    Database link: Q9UBK2

  • General notes

    This product may be covered by one or more of the following U.S. Patents.

    6,166,192
    6,426,411
    6,525,178
    6,872,391
    6,908,987
    7,250,283
    7,091,006
    7,354,738
    8,105,774
    8,445,233

     

Applications

Our Abpromise guarantee covers the use of ab51365 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Dot blot Use at an assay dependent dilution.
WB Use at an assay dependent dilution. Predicted molecular weight: 89 kDa.

Target

  • FunctionTranscriptional coactivator for steroid receptors and nuclear receptors. Greatly increases the transcriptional activity of PPARG and thyroid hormone receptor on the uncoupling protein promoter. Can regulate key mitochondrial genes that contribute to the program of adaptive thermogenesis. Plays an essential role in metabolic reprogramming in response to dietary availability through coordination of the expression of a wide array of genes involved in glucose and fatty acid metabolism. Induces the expression of PERM1 in the skeletal muscle in an ESRRA-dependent manner. Also involved in the integration of the circadian rhythms and energy metabolism. Required for oscillatory expression of clock genes, such as ARNTL/BMAL1 and NR1D1, through the coactivation of RORA and RORC, and metabolic genes, such as PDK4 and PEPCK.
  • Tissue specificityHeart, skeletal muscle, liver and kidney. Expressed at lower levels in brain and pancreas and at very low levels in the intestine and white adipose tissue. In skeletal muscle, levels were lower in obese than in lean subjects and fasting induced a 2-fold increase in levels in the skeletal muscle in obese subjects.
  • Sequence similaritiesContains 1 RRM (RNA recognition motif) domain.
  • Post-translational
    modifications
    Phosphorylation by AMPK in skeletal muscle increases activation of its own promoter. Phosphorylated by CLK2.
    Heavily acetylated by GCN5 and biologically inactive under conditions of high nutrients. Deacetylated by SIRT1 in low nutrients/high NAD conditions.
    Ubiquitinated. Ubiquitination by RNF34 induces proteasomal degradation.
  • Cellular localizationCytoplasm. Nucleus; Nucleus and Nucleus. Nucleus, PML body.
  • Information by UniProt
  • Database links
  • Alternative names
    • L PGC 1alpha antibody
    • LEM6 antibody
    • Ligand effect modulator 6 antibody
    • Peroxisome proliferative activated receptor gamma coactivator 1 alpha antibody
    • Peroxisome proliferative activated receptor gamma coactivator 1 antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4 3ext antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4 8a antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4 antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B5 antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B5 NT antibody
    • Peroxisome proliferator-activated receptor gamma coactivator 1-alpha antibody
    • PGC 1 (alpha) antibody
    • PGC 1 alpha antibody
    • PGC 1v antibody
    • PGC-1-alpha antibody
    • PGC1 antibody
    • PGC1(alpha) antibody
    • PGC1A antibody
    • PGC1v antibody
    • PPAR gamma coactivator 1 alpha 3 ligand effect modulator 6 antibody
    • PPAR gamma coactivator 1 alpha antibody
    • PPAR gamma coactivator 1 antibody
    • PPAR gamma coactivator variant form antibody
    • PPAR-gamma coactivator 1-alpha antibody
    • PPARGC 1 alpha antibody
    • PPARGC-1-alpha antibody
    • PPARGC1 antibody
    • PPARGC1A antibody
    • PRGC1_HUMAN antibody
    see all

Anti-PGC1 alpha antibody [PPARAH6] images

  • Anti-PGC1 alpha antibody [PPARAH6] (ab51365) + Recombinant protein fragment (immunogen)

    Predicted band size : 89 kDa

References for Anti-PGC1 alpha antibody [PPARAH6] (ab51365)

This product has been referenced in:
  • Anderson EJ  et al. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 54:1891-8 (2009). WB ; Human . Read more (PubMed: 19892241) »
  • Chichelnitskiy E  et al. In vivo phosphoenolpyruvate carboxykinase promoter mapping identifies disrupted hormonal synergism as a target of inflammation during sepsis in mice. Hepatology 50:1963-71 (2009). WB ; Mouse . Read more (PubMed: 19821526) »

See all 2 Publications for this product

Product Wall

Abcam has not validated the combination of species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (human hepatocellular carcinoma)
Loading amount 30 µg
Specification human hepatocellular carcinoma
Gel Running Conditions Reduced Denaturing (10 and 12 % gel)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Ms. Hui-Tzu Hsu

Verified customer

Submitted Apr 03 2012

Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products.

Indeed, the abreview has been submitted correctly, however, we unfortunately did not receive the i...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"